You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The method, dubbed GoPhAST-R, was codeveloped by researcher from the Broad Institute and NanoString, which now hopes to work with a partner to commercialize it.
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The firm plans to launch 10 new products next year, but analysts were cautious about Quidel's prospects moving forward.
Isothermal molecular assays to diagnose a parasitic infection that afflicts approximately 300 million people are moving closer to commercialization.
After years of frustration, researchers can now more definitively link a polio-like syndrome to prior infection with two common respiratory viruses.
The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.
New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.